Bernstein analyst Lance Wilkes maintained a Hold rating on Humana (HUM – Research Report) yesterday and set a price target of $420.00. The company’s shares closed yesterday at $346.83.
Wilkes covers the Healthcare sector, focusing on stocks such as Cigna, HCA Healthcare, and Centene. According to TipRanks, Wilkes has an average return of 15.2% and a 69.44% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Humana with a $425.31 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $538.11 and a one-year low of $342.69. Currently, Humana has an average volume of 2.05M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana (HUM) Company Description:
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
Read More on HUM:
- Trump vs. Biden: Which Stocks to Choose for Each Election Outcome
- AdaptHealth price target raised to $13 from $11 at Truist
- Humana in starategic partnership with for accurracy in provider directories
- Starboard takes new stakes in Fortrea, News Corp
- Humana Inc. Faces Unexpected Medicare Funding Challenges
